109 results on '"Waters, David D."'
Search Results
2. Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now
3. High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study)
4. Lipid Abnormalities in Persons Living With HIV Infection
5. Variations in time to benefit among clinical trials of cholesterol-lowering drugs
6. Visit-to-visit variability of lipid measurements as predictors of cardiovascular events
7. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk
8. An Evidence-Based Guide to Cholesterol-Lowering Guidelines
9. Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial
10. Metabolic Markers to Predict Incident Diabetes Mellitus in Statin-Treated Patients (from the Treating to New Targets and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trials)
11. Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study)
12. 2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?
13. Impact of Female Sex on Lipid Lowering, Clinical Outcomes, and Adverse Effects in Atorvastatin Trials
14. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
15. Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials
16. Effect of Change in Body Weight on Incident Diabetes Mellitus in Patients With Stable Coronary Artery Disease Treated With Atorvastatin (from the Treating to New Targets Study)
17. Impact of High-Dose Atorvastatin Therapy and Clinical Risk Factors on Incident Aortic Valve Stenosis in Patients With Cardiovascular Disease (from TNT, IDEAL, and SPARCL)
18. Relation of Improvement in Estimated Glomerular Filtration Rate With Atorvastatin to Reductions in Hospitalizations for Heart Failure (from the Treating to New Targets [TNT] Study)
19. Comparison of Lipid Profiles and Attainment of Lipid Goals in Patients
20. Carotid Intima-Media Thickness Among Human Immunodeficiency Virus–Infected Patients Without Coronary Calcium
21. 85 - Cardiovascular Abnormalities in HIV-Infected Individuals
22. Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin: Results From 3 Large Randomized Clinical Trials
23. Reaching C-Reactive Protein and Low-Density Lipoprotein Cholesterol Goals in Dyslipidemic Patients (from the Lipid Treatment Assessment Project [L-TAP] 2)
24. Impact of Smoking on Cardiovascular Events in Patients With Coronary Disease Receiving Contemporary Medical Therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trials)
25. Usefulness of Heart Rate at Rest as a Predictor of Mortality, Hospitalization for Heart Failure, Myocardial Infarction, and Stroke in Patients With Stable Coronary Heart Disease (Data from the Treating to New Targets [TNT] Trial)
26. A winter’s tale: Report from the First Annual Canadian Biomarkers and Surrogate Endpoints Symposium
27. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A 2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial
28. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2
29. Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease
30. Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery
31. Comparison of Effectiveness of Atorvastatin 10 mg Versus 80 mg in Reducing Major Cardiovascular Events and Repeat Revascularization in Patients With Previous Percutaneous Coronary Intervention (Post Hoc Analysis of the Treating to New Targets [TNT] Study)
32. Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients With Stable Coronary Disease in the TNT (Treating to New Targets) Study
33. Effects of Statin Therapy on the Development and Progression of Heart Failure: Mechanisms and Clinical Trials
34. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study
35. 82 - Anomalías cardiovasculares en personas infectadas por el VIH
36. 82 - Cardiovascular Abnormalities in HIV-Infected Individuals
37. Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) trial
38. Safety of High-Dose Atorvastatin Therapy
39. Contributors
40. American College of Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert Consensus Document on Cardiac Catheterization Laboratory Standards : A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents endorsed by the American Heart Association and the Diagnostic and Interventional Catheterization Committee of the Council on Clinical Cardiology of the AHA
41. Synergy between intracoronary stenting and abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction
42. Short- and medium-term outcome differences in women and men after primary percutaneous transluminal mechanical revascularization for acute myocardial infarction
43. Comparison of electrocardiographic-gated technetium-99m sestamibi single-photon emission computed tomographic imaging and rest-redistribution thallium-201 in the prediction of myocardial viability
44. Will Colchicine Soon Be Part of Primary and Secondary Cardiovascular Prevention?
45. Comparison of acute rest myocardial perfusion imaging and serum markers of myocardial injury in patients with chest pain syndromes
46. Impact of limited treadmill exercise on adenosine Tc-99m sestamibi single-photon emission computed tomographic myocardial perfusion imaging in coronary artery disease
47. Erratum to “Notes From Cardiology Clinic: The Patients We Dislike”: Can J Cardiol 36 (2020) 157-158
48. When Diastole Lets You Down: Clinical Relevance of a Widened Pulse Pressure
49. WITHDRAWN: Notes From Cardiology Clinic: The Patients We Dislike
50. Risk of New-Onset Diabetes and Cardiovascular Risk Reduction From High-Dose Statin Therapy in Pre-Diabetics and Non–Pre-Diabetics: An Analysis From TNT and IDEAL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.